Clinical Trial Update: MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MRD-adaptive guided CAR-T immunotherapy in transplant-ineligible patients with multiple myeloma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma, Newly Diagnosed | Phase 2 | Status: RECRUITING